$ 19.32
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of SRPT is 22 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
